Literature DB >> 12480965

PRE-dialysis survey on anaemia management.

Fernando Valderrábano1, Walter H Hörl, Iain C Macdougall, Jérôme Rossert, Boleslaw Rutkowski, Jean-Pierre Wauters.   

Abstract

BACKGROUND: The PRE-dialysis survey on anaemia management (PRESAM) was designed to assess the care given to pre-dialysis patients in the 12 months before haemodialysis or peritoneal dialysis, with emphasis on anaemia management.
METHODS: For this epidemiological study, a retrospective chart review was conducted for patients who started haemodialysis or peritoneal dialysis between 1 August, 1999 and 6 April, 2000. All adult patients who entered one of the 779 participating centres in 21 European countries, Israel or South Africa were included, except for patients who underwent dialysis only during an acute episode. In addition to demographic characteristics, the study examined the prevalence of anaemia, anaemia management including the use of iron supplementation and epoetin, source of referral to the dialysis centre, comorbidities and major clinical events.
RESULTS: A total of 4333 new dialysis patients were included in the survey. At the first visit to the dialysis centre, 68% of the patients had a haemoglobin (Hb) concentration < or = 11.0 g/dl; Hb concentration was positively correlated with creatinine clearance rate (r = 0.43, P < 0.01). Patients who received epoetin had a mean Hb concentration of 8.8 g/dl at the start of epoetin treatment, and 96% of these patients had an Hb concentration < or = 11.0 g/dl. Only 26.5% of the patients received epoetin before dialysis. The length of time under the care of a nephrologist was associated with meeting the European Best Practice Guidelines (EBPG) target Hb concentration, as well as receiving epoetin.
CONCLUSIONS: Few pre-dialysis patients met the EBPG target for Hb concentration, despite regular nephrology care.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12480965     DOI: 10.1093/ndt/18.1.89

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  20 in total

1.  A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.

Authors:  Iain C Macdougall; William E Strauss; Justin McLaughlin; Zhu Li; Frank Dellanna; Joachim Hertel
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

Review 2.  Intravenous iron in heart failure: beyond targeting anemia.

Authors:  Donald S Silverberg; Adrian Iaina; Doron Schwartz; Dov Wexler
Journal:  Curr Heart Fail Rep       Date:  2011-03

3.  Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Authors:  Stefan Heidenreich; Frank Leistikow; Stefan Zinn; Jörg Baumann; Andreas Atzeni; Vitomir Bajeski; Jörn Dietzmann; Gert-Peter Dragoun
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

4.  De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.

Authors:  Bradley A Warady; John Barcia; Nadine Benador; Augustina Jankauskiene; Kurt Olson; Ludmila Podracka; Aleksey Shavkin; Poyyapakkam Srivaths; Cynthia J Wong; Jeffrey Petersen
Journal:  Pediatr Nephrol       Date:  2017-08-17       Impact factor: 3.714

Review 5.  Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.

Authors:  Donald S Silverberg; Dov Wexler; Adrian Iaina; Shoshana Steinbruch; Y Wollman; Doron Schwartz
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

6.  Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study.

Authors:  Charalampos Loutradis; Alexandra Skodra; Panagiotis Georgianos; Panagiota Tolika; Dimitris Alexandrou; Afroditi Avdelidou; Pantelis A Sarafidis
Journal:  World J Nephrol       Date:  2016-07-06

7.  Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia.

Authors:  Nathalie Thilly; Bénédicte Stengel; Stéphanie Boini; Emmanuel Villar; Cécile Couchoud; Luc Frimat
Journal:  Nephron Clin Pract       Date:  2008-01-08

8.  Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study.

Authors:  Rafael Pérez-García; Alejandro Martín-Malo; Joan Fort; Xavier Cuevas; Fina Lladós; Javier Lozano; Fernando García
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

9.  Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data.

Authors:  Olga Dmitrieva; Simon de Lusignan; Iain C Macdougall; Hugh Gallagher; Charles Tomson; Kevin Harris; Terry Desombre; David Goldsmith
Journal:  BMC Nephrol       Date:  2013-01-25       Impact factor: 2.388

10.  Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis.

Authors:  Luc Frimat; Christophe Mariat; Paul Landais; Sébastien Koné; Bénédicte Commenges; Gabriel Choukroun
Journal:  BMJ Open       Date:  2013-03-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.